- Home
- IOBT vs LTRN Comparison
IOBT vs LTRN Comparison
Compare IOBT & LTRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IOBT
- LTRN
- Stock Information
- Founded
- IOBT 2014
- LTRN 2013
- Country
- IOBT Denmark
- LTRN United States
- Employees
- IOBT N/A
- LTRN N/A
- Industry
- IOBT Biotechnology: Pharmaceutical Preparations
- LTRN Biotechnology: Pharmaceutical Preparations
- Sector
- IOBT Health Care
- LTRN Health Care
- Exchange
- IOBT Nasdaq
- LTRN Nasdaq
- Market Cap
- IOBT 57.9M
- LTRN 46.7M
- IPO Year
- IOBT 2021
- LTRN 2020
- Fundamental
- Price
- IOBT $1.16
- LTRN $3.80
- Analyst Decision
- IOBT Strong Buy
- LTRN Hold
- Analyst Count
- IOBT 3
- LTRN 1
- Target Price
- IOBT $9.33
- LTRN N/A
- AVG Volume (30 Days)
- IOBT 213.3K
- LTRN 29.2K
- Earning Date
- IOBT 05-13-2025
- LTRN 03-27-2025
- Dividend Yield
- IOBT N/A
- LTRN N/A
- EPS Growth
- IOBT N/A
- LTRN N/A
- EPS
- IOBT N/A
- LTRN N/A
- Revenue
- IOBT N/A
- LTRN N/A
- Revenue This Year
- IOBT $59.29
- LTRN N/A
- Revenue Next Year
- IOBT N/A
- LTRN N/A
- P/E Ratio
- IOBT N/A
- LTRN N/A
- Revenue Growth
- IOBT N/A
- LTRN N/A
- 52 Week Low
- IOBT $0.66
- LTRN $2.79
- 52 Week High
- IOBT $1.79
- LTRN $9.96
- Technical
- Relative Strength Index (RSI)
- IOBT 67.95
- LTRN 51.15
- Support Level
- IOBT $0.90
- LTRN $3.58
- Resistance Level
- IOBT $1.37
- LTRN $4.01
- Average True Range (ATR)
- IOBT 0.10
- LTRN 0.24
- MACD
- IOBT 0.03
- LTRN 0.04
- Stochastic Oscillator
- IOBT 60.97
- LTRN 98.05
About IOBT IO Biotech Inc.
IO Biotech Inc is a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on T-win technology platform. The product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression.
About LTRN Lantern Pharma Inc.
Lantern Pharma Inc is an AI company transforming the cost, pace, and timeline of oncology drug discovery and development. Its proprietary AI and machine learning (ML) platform, RADR, uses oncology-focused data points and advanced ML algorithms to solve billion-dollar, real-world problems in cancer drug development. The group's growing pipeline of precision therapies has been accelerated using AI and input from world-class scientific advisors and collaborators.